JO
MGX icon

John Overdeck’s Metagenomi Therapeutics MGX Stock Holding History

John Overdeck’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
513,701
+16,934
+3% +$22.7K ﹤0.01% 4003
2026
Q1 		$666K Buy
496,767
+55,379
+13% +$86K ﹤0.01% 3533
2025
Q4 		$715K Buy
441,388
+233,860
+113% +$506K ﹤0.01% 3124
2025
Q3 		$492K Buy
207,528
+193,641
+1,394% +$393K ﹤0.01% 2994
2025
Q2 		$20.6K Sell
13,887
-44,461
-76% -$69.6K ﹤0.01% 3117
2025
Q1 		$79.4K Buy
58,348
+31,877
+120% +$76K ﹤0.01% 2991
2024
Q4 		$95.6K Sell
26,471
-59,135
-69% -$143K ﹤0.01% 2974
2024
Q3 		$186K Buy
85,606
+47,912
+127% +$166K ﹤0.01% 2811
2024
Q2 		$154K Buy
37,694
+17,535
+87% +$120K ﹤0.01% 2776
2024
Q1 		$213K Buy
+20,159
New +$232K ﹤0.01% 2691

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's MGX Position: Q2 2026 in Review

John Overdeck increased its Metagenomi Therapeutics (MGX) stake by 3.4% in Q2 2026, buying an estimated $22.7K and bringing the position to 513,701 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

John Overdeck first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $715K in Q4 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • John Overdeck held 513,701 shares of Metagenomi Therapeutics worth $611K as of Q2 2026.
  • John Overdeck bought 16,934 Metagenomi Therapeutics shares in Q2 2026, an estimated $22.7K.
  • Metagenomi Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4003 holding.
  • John Overdeck first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • John Overdeck's Metagenomi Therapeutics position peaked at $715K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.